Summary: A precision neuro-pharmacology and molecular pain study mapped the exact pathological mechanism linking HIV infection to chronic neuropathic pain. The research utilizes mammalian models to demonstrate how a specific viral envelope protein named glycoprotein 120 (gp120) drop-shocks the nervous system into a state of permanent hyper-sensitization.
By exposing how gp120 forces the overactivation of spinal nerve receptors within targeted neuron populations, the study provides a definitive biological blueprint to reverse viral pain hypersensitivity and design hyper-precise, non-addictive treatments for chronic suffering.
Key Facts
- The Intractable HIV Pain Epidemic: Chronic pain stands as an exceptionally widespread and difficult-to-treat medical crisis within neuro-virology, with over half of all individuals carrying HIV experiencing debilitating pain at some point. Current pharmaceutical standards are highly ineffective, primarily because the underlying molecular pathways driving this viral nerve suffering have historically remained unmapped.
- The gp120 Intersection: Led by Principal Investigator Hui-Lin Pan, researchers built upon separate lines of historical data. Previous neuroscience literature had independently connected the HIV viral protein glycoprotein 120 (gp120) to elevated pain hypersensitivity, while separately linking overactive signaling of a specific type of spinal nerve receptor to chronic nerve pain. Pan’s team bridged these fields to test if the viral protein directly hijacks that exact receptor.
- Amplifying the Spinal Gateway: To isolate the cellular mechanics, the team delivered direct micro-injections of the gp120 protein into the spinal cords of mouse models. The viral protein immediately and aggressively amplified the spinal nerve receptor’s electrical signaling activity, proving that the viral asset actively rewires the spinal cord’s threshold for processing pain.
- Isolating the Cellular Target: The research team demonstrated that this gp120-induced receptor amplification is not a generic, systemic blur, but an elegant mechanism that selectively targets and alters a highly specific, localized neuron population inside the spine.
- Reversing the Hypersensitivity Mechanism: Armed with this structural roadmap, investigators deployed a sophisticated combination of drug-based (pharmacological) and genetic engineering approaches to target the molecular players involved in the pathway. By disrupting this specific protein interaction, the researchers successfully reversed the mechanism they identified and completely reduced pain hypersensitivity in the models.
- A Universal Precision Roadmap: This molecular breakthrough shifts pain management away from blunt, systemic numbing agents toward hyper-targeted therapies. Professor Pan is actively moving forward to engineer precise strategies designed to disrupt protein interactions with the spinal nerve receptor, a framework that could yield highly effective treatments for chronic neuropathic pain born from HIV as well as an array of other non-viral chronic conditions.
Source: SfN
Over half of the people carrying HIV experience chronic pain at some point, which is difficult to treat. In a new Journal of Neuroscience paper, Hui-Lin Pan, from The University of Texas MD Anderson Cancer Center, and colleagues used mice to explore how HIV leads to chronic pain.
Previous research separately linked a viral protein called glycoprotein 120 (gp120) to increased pain sensitivity and overactive signaling of a type of nerve receptor in the spine to nerve pain. Informed by these findings, the researchers sought to investigate whether gp120 influences signaling of this nerve receptor.
Injecting gp120 into the spine of mice increased the nerve receptor’s activity through a mechanism that affected a specific neuron population. Using a combination of drug-based and genetic approaches targeting the molecular players involved, the researchers discovered they could reverse the mechanism they identified and reduce pain hypersensitivity in the mice.
According to the researchers, this work shows how an HIV-associated protein amplifies pain signaling in the spinal cord and shows that disrupting this mechanism may lessen pain sensitivity.
Pan looks forward to continuing this work, saying, “We are particularly excited about developing therapeutic approaches to disrupt [this mechanism, specifically by targeting protein interactions with the nerve receptor]. These targeted strategies may provide more precise and effective treatments for chronic neuropathic pain, not only in HIV, but potentially in other conditions as well.”
Key Questions Answered:
A: Because the pain is caused by a viral protein that physically rewires the nervous system. MD Anderson’s research reveals that the HIV protein gp120 acts like an absolute volume dial inside the spinal cord. It drops straight into the spine and forces specific nerve receptors to become hyperactive, making the nervous system experience normal sensations as intense, chronic neuropathic pain. Since traditional painkillers do not treat this structural cellular hijacking, they fail to deliver relief.
A: By using a dual drug-based and genetic approach to target only the specific molecular players involved. Once the scientists mapped the exact pathway the gp120 protein uses to alter a targeted neuron population, they deployed precision tools to block that specific interaction. This targeted strategy allowed them to reverse the hyper-sensitization and safely drop the models’ pain levels back to normal.
A: Because the underlying spinal nerve receptor hijacked by HIV is the same highway involved in many other types of chronic pain. By engineering a strategy that blocks proteins from binding to and hyper-activating this specific nerve receptor, MD Anderson is building a universal therapeutic blueprint. This precise method can eventually be customized to shut down chronic neuropathic pain across a wide range of different trauma, disease, and nerve conditions.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this HIV and pain research news
Author: SfN Media
Source: SfN
Contact: SfN Media – SfN
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“HIV-1 gp120 Induces Nociceptive Hypersensitivity via α2δ-1–bound NMDA Receptors at Primary Afferent-Excitatory Neuron Synapses” by Vipasha Gautam, Yuying Huang (黄玉莹), Hong Chen (陈红), Shao-Rui Chen (陈少瑞) and Hui-Lin Pan (潘惠麟). Journal of Neuroscience
DOI:10.1523/JNEUROSCI.0368-26.2026
Abstract
HIV-1 gp120 Induces Nociceptive Hypersensitivity via α2δ-1–bound NMDA Receptors at Primary Afferent-Excitatory Neuron Synapses
HIV-1 infection often results in sensory neuropathy, with more than 60% of affected individuals developing chronic pain. Although viral proteins such as glycoprotein 120 (gp120) contribute to neuronal injury and pain hypersensitivity, their specific effects on nociceptive signaling remain unclear. Hyperactivity of N-methyl-D-aspartate receptor (NMDAR) in the spinal dorsal horn is a hallmark of neuropathic pain.
Here, we determined how gp120 affects synaptic NMDAR activity in spinal excitatory and inhibitory neurons in male and female mice. Intrathecal gp120 enhanced expression of α2δ-1 and GluN1 in the dorsal root ganglion and spinal cord. Gp120 also increased α2δ-1–GluN1 interaction and their synaptic trafficking in the spinal cord.
Functionally, gp120 induced hyperactivity of presynaptic NMDARs on primary afferent terminals and postsynaptic NMDARs in vesicular glutamate transporter 2 (VGluT2)–expressing excitatory, but not vesicular GABA/glycine transporter (VGAT)–expressing inhibitory, dorsal horn neurons. Importantly, gp120-induced hyperactivity of both presynaptic and postsynaptic NMDARs was eliminated by the α2δ-1 inhibitory ligand gabapentin or by an α2δ-1 C-terminal peptide that disrupts α2δ-1–NMDAR interactions.
Correspondingly, treatment with the NMDAR antagonist, gabapentin, or α2δ-1 C-terminal peptide consistently reversed gp120-induced persistent nociceptive hypersensitivity. Furthermore, genetic deletion of Cacna2d1 or selective ablation of GluN1 in dorsal root ganglion neurons significantly attenuated gp120-induced nociceptive hypersensitivity.
Together, these findings indicate that gp120 drives nociceptive hypersensitivity by augmenting presynaptic and postsynaptic activity of α2δ-1–bound NMDARs, thereby amplifying nociceptive transmission from primary afferents to spinal excitatory neurons. Targeting α2δ-1–associated NMDARs may therefore represent a promising therapeutic approach for HIV-associated chronic neuropathic pain.
